智翔金泰：截至2025年9月30日，公司已收到GR1803注射液授权许可与商业化协议的首付款2000万美元

Group 1 - The company, Zhixiang Jintai, announced on October 31 that it has received a first payment of $20 million for the GR1803 injection licensing and commercialization agreement, which is expected to be completed by September 30, 2025 [1]